1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies, today announced the final closing of its $200 million inaugural fund. The fund is led by seasoned healthcare investors and 1315 Capital's Co-Founders, Adele Oliva and Michael Koby, and includes a select group of high quality investors, including endowments, foundations, state and corporate pension funds, and family offices.

"We are very pleased with the positive reception to 1315 Capital's team and investment model," said Oliva. "Consolidation within healthcare has provided opportunities for innovation, particularly in niche markets, and we are committed to working with exceptional management teams to fill needs in the healthcare market and build value for our investors."

1315 Capital's Operating Partner model is unique in that teams of two executives, who have worked together at multiple companies, are engaged with the firm's investment team and portfolio companies, adding valuable human capital to the investment equation.

"Our unique Operating Partner model leverages not only the CEO, but also the Chairman, COO, and CFO relationships, allowing us to provide a more complete set of skills to help navigate diligence, drive decisions, and achieve premium exits," said Koby.

About 1315 Capital 

1315 Capital provides venture expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies. Led by co-founders Adele Oliva and Michael Koby, 1315 Capital partners its fast-growing portfolio companies with experienced investors as well as high-quality executives through its unique Operating Partner model.

For more information, visit www.1315capital.com or email team@1315capital.com